主要 报价 日历 论坛
flag

FX.co ★ Sanofi Announces Expanded Marketing Authorization For Sarclisa In The EU - Quick Facts

back back next
typeContent_19130:::2025-01-22T06:17:00

Sanofi Announces Expanded Marketing Authorization For Sarclisa In The EU - Quick Facts

Sanofi has announced that the European Union has approved Sarclisa for use in combination with a standard-of-care regimen, specifically bortezomib, lenalidomide, and dexamethasone. This approval applies to the treatment of adult patients newly diagnosed with multiple myeloma who are not eligible for autologous stem cell transplants. The decision was based on data from the phase 3 IMROZ study. With this expanded marketing authorization, Sarclisa becomes the first anti-CD38 therapy to be approved in combination with this regimen for this particular patient group within the EU.

Sarclisa has now been approved in over 50 countries, including both the United States and the European Union, for three clinical indications.

分享此文章:
back back next
loader...
all-was_read__icon
你现在看过所有最好的出版物。
我们已经在寻找一些有趣的东西......
all-was_read__star
最近发表:
loader...
最近的出版物